Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Cholesterol drugs may curb strokes among low-risk older adults

(Reuters Health) – Cholesterol-lowering drugs such as statins may reduce the risk of stroke in low-risk elderly patients, a French study suggests. People who took statins or fibrates, another type of cholesterol-lowering medicine, were 34 percent less likely to have a stroke than those who didn’t, researchers report. “If confirmed, these results are compatible with […]

Read More »

Novo Nordisk weighs diabetes drug’s use in fatty liver disease

Novo Nordisk is looking into recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease, a hot area for pharmaceutical development. Research from Britain’s University of Birmingham showed last month that the drug, also known as liraglutide, resolved fatty liver disease in more than a third […]

Read More »

U.S. FDA warns on newer class of type 2 diabetes drugs

The headquarters of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, in this file photo taken on November 4, 2009. Reuters/Jason Reed The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli […]

Read More »

U.S. FDA warns on newer class of type 2 diabetes drugs

The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The drugs belong to a class known as SGLT2 […]

Read More »

Indian court bars Glenmark from selling Merck drug copies

India’s Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck’s diabetes drugs Januvia and Janumet, according to a court document released on Friday. The court has, however, allowed Glenmark to continue to sell existing inventory, according to the document posted on the Supreme Court’s website after a hearing. The […]

Read More »

AbbVie Receives Orphan Drug Designation for HUMIRA from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS)

NORTH CHICAGO, Ill., May 15, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie’s supplemental Biologic License Application seeking […]

Read More »

What The Travails Of The UK’s Largest Grocer Can Teach The Pharmaceutical Industry

In the five years since the first DrugBaron article was published, entitled “Hard Times, Harder Times,” it seems that in the business of drug discovery and development everything has changed – and at the same time nothing. On the one hand, the ubiquitous gloom that surrounded the industry has lifted, to be replaced with a febrile […]

Read More »

Did Orexigen Have The Right To File Its Controversial Patent?

Shares in Orexigen Therapeutics, the maker of a weight-loss drug called Contrave, have dropped 24%  to $5 since Tuesday, when news came out that data that the drug maker had originally presented as showing Contrave prevented heart attacks and strokes were part of a study that, in the end, showed no such thing. The news was […]

Read More »

Type of B vitamin shown to reduce risk of common skin cancers

A simple daily vitamin may help prevent the most common types of skin cancer in people at high risk of the disease, according to new research from Australia. A study conducted at the University of Sydney found that nicotinamide, a form of vitamin B3, reduced by 23 percent the incidence of new, non-melanoma skin cancers […]

Read More »

Roche immunotherapy improves lung cancer survival

A mid-stage trial of Roche Holding AG’s experimental immunotherapy showed that it doubled the likelihood of survival for lung cancer patients with the highest levels of a specific biomarker. The drug, known by the code name MPDL3280A, is part of a new class designed to help the body’s immune system fend off cancer by blocking […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom